731 related articles for article (PubMed ID: 10353736)
1. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma.
Mohr M; Dalmis F; Hilgenfeld E; Oelmann E; Zühlsdorf M; Kratz-Albers K; Nolte A; Schmitmann C; Onaldi-Mohr D; Cassens U; Serve H; Sibrowski W; Kienast J; Berdel WE
Clin Cancer Res; 2001 Jan; 7(1):51-7. PubMed ID: 11205918
[TBL] [Abstract][Full Text] [Related]
3. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
Han X; Shi Y; Zhang W
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
[TBL] [Abstract][Full Text] [Related]
4. Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells.
Hoppe B; Mohr M; Roots-Weiss A; Kienast J; Berdel WE
Bone Marrow Transplant; 1999 Apr; 23(8):809-17. PubMed ID: 10231144
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.
Yanovich S; Mitsky P; Cornetta K; Maziarz RT; Rosenfeld C; Krause DS; Lotz JP; Bitran JD; Williams S; Preti R; Somlo G; Burtness B; Mills B
Bone Marrow Transplant; 2000 Jun; 25(11):1165-74. PubMed ID: 10849529
[TBL] [Abstract][Full Text] [Related]
7. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
8. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
10. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
11. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
13. Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis.
Locatelli F; Perotti C; Torretta L; Maccario R; Montagna D; Ravelli A; Giorgiani G; De Benedetti F; Giraldi E; Magnani ML; De Stefano P; Martini A
Haematologica; 1999 Sep; 84(9):839-43. PubMed ID: 10477459
[TBL] [Abstract][Full Text] [Related]
14. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
15. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Cowan KH; Moscow JA; Huang H; Zujewski JA; O'Shaughnessy J; Sorrentino B; Hines K; Carter C; Schneider E; Cusack G; Noone M; Dunbar C; Steinberg S; Wilson W; Goldspiel B; Read EJ; Leitman SF; McDonagh K; Chow C; Abati A; Chiang Y; Chang YN; Gottesman MM; Pastan I; Nienhuis A
Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
[TBL] [Abstract][Full Text] [Related]
18. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
19. Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer.
Okumura A; Tokuda Y; Ohta M; Suzuki Y; Saito Y; Kuge S; Kubota M; Makuuchi H; Tajima T; Nakamura Y; Hotta T
Tokai J Exp Clin Med; 1999 Dec; 24(4-6):141-6. PubMed ID: 10819494
[TBL] [Abstract][Full Text] [Related]
20. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
